NCT05355753View on ClinicalTrials.gov

A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors

PHASE1TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

March 25, 2022

Primary Completion Date

December 19, 2023

Study Completion Date

December 19, 2023

Conditions
Synovial SarcomaSoft Tissue Sarcoma
Interventions
DRUG

CFT8634

Oral dose of CFT8634

Trial Locations (12)

10021

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center, New York

10027

Columbia University, New York

32224

Mayo Clinic - Jacksonville, Jacksonville

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

52242

University of Iowa Hospital and Clinics, Iowa City

55905

Mayo Clinic - Rochester, Rochester

63110

Washington University School of Medicine, St Louis

77030

MD Anderson Cancer Center, Houston

80045

University of Colorado - Aurora Cancer Center, Aurora

90403

Sarcoma Oncology Research Center, Santa Monica

91010

City of Hope, Duarte

02114

Massachusetts General Hospital, Boston

Sponsors
All Listed Sponsors
lead

C4 Therapeutics, Inc.

INDUSTRY

NCT05355753 - A Study to Assess the Safety and Tolerability of CFT8634 in Locally Advanced or Metastatic SMARCB1-Perturbed Cancers, Including Synovial Sarcoma and SMARCB1-Null Tumors | Biotech Hunter | Biotech Hunter